Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Geron Corporation

Geron is engaged in the development of innovative medicines for myeloid hematologic malignancies. The company focuses on research and development, particularly in telomerase inhibition.

Metric
Company Name	Geron Corporation
Symbol	GERN
MSH ID	COM:GERON
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	141
Website	geron.com
LinkedIn
Founders

Metric
Market Cap	2.73B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	237K
Revenue (LTM)
Revenue (NTM)
Gross Profit	-796.00K
EBITDA	-192.91M
Operating Income	-193.94M
Net Income	-184.13M
EPS	-0.32
Diluted EPS	-0.32
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-21.13
Operating Profit Margin	-165.60
EBITDA Margin	-813.97
Net Profit Margin	-159.91
Return on Equity	-0.63
Return on Assets	-0.42
Return on Capital Employed	-0.59

COM:GERON

Geron

Last Close

4.02

22/11 21:00

Market Cap

2.73B

Beta: -

Volume Today

6.85M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-6.06
P/B Ratio	3.64
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	10.12K
EV Multiple	-9.67

Metric
Days Sales Outstanding	16.99K
Days Payables Outstanding
Days Inventory Outstanding	9.30
Operating Cycle	2.55K
Cash Conversion Cycle	2.47K
Asset Turnover	0.00

Metric
Operating Cash Flow	-167.10M
Free Cash Flow	-167.93M
Cash Flow to Debt	-2.02
Operating Cash Flow/Sales	-150.67
Free Cash Flow Yield	-0.16

Metric
Cash & Equivalents	71.14M
Accounts Receivable	1.49M
Inventory
Goodwill
Debt to Capitalization	0.25
Debt to Assets	0.14
Current Ratio	3.75
Quick Ratio	3.67

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	51.41
R&D to Revenue	379.64
SG&A to Revenue	194.25